Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and
Piramal Pharma Q4FY23 Earnings Story
Categories
Pharmaceutical
Natco Pharma Q4FY23 Earnings Story
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products
Jubilant Pharmova Q4FY23 Earnings Story
The three business components of Jubilant Pharmova Ltd, which include medicines, contract research and development services, and patented new therapies, make up
Pfizer Limited Q4FY23 Earnings Story
Pharmaceutical product manufacture, marketing, trade, and export are all activities of Pfizer Ltd. It produces goods in-house and also works with several
Medico Remedies Q4FY23 Earnings Story
Medico Remedies is engaged in the business of Manufacture of allopathic pharmaceutical preparations. Financial Results: Medico Remedies Limited reported Total Income for
Neuland Laboratories Q4FY23 Earnings Story
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Orchid Pharma Limited Q4FY23 Earnings Story
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It
Lupin Limited Q4FY23 Earnings Story
Lupin manufactures pharmaceuticals as a line of business. Globally, APIs, biotechnology products, and generic formulations are all developed and marketed by Lupin
Syngene International Ltd (SYNGENE) Q4 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE:SYNGENE) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Avantika Mishra -- Investor Relations Jonathan Hunt -- Managing Director and Chief
Panacea Biotec Limited: Making India Healthier
Panacea Biotec Limited is an Indian pharmaceutical company that is engaged in research, development, and manufacturing of pharmaceuticals, vaccines, and natural products.
Can Jubilant Pharmova leverage their position?
“In FY24, Company’s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in
Glenmark Pharmaceuticals: An Uphill Battle
“Strategic priority is to enhance our free cash generation and further debt reduction and we continue discussion with potential partners for out-licensing
Sun Pharma Advanced Research Q3FY23 Earnings
(SPARC) Sun Pharma Advanced Research Company Limited conducts pharmaceutical product research and development (R&D). Financial Results: After nine consecutive quarters of losses,
Shilpa Medicare Limited Q3FY23 Earnings
With cutting-edge technology, Shilpa Medicare is in the business of manufacturing high-quality Active Pharmaceutical Ingredients, Intermediates, Formulations, Novel Drug delivery system, Peptides,
Sanofi India Limited Q3FY23 Earnings Story
Sanofi India primarily deals with the Manufacture and sale of pharmaceutical products. Financial Results: The company reported a decline of 2.32% YoY
Procter & Gamble Health Q2FY23 Earnings Story
Procter & Gamble Health Ltd. primarily deals with both manufacturing and marketing various chemicals and pharmaceuticals. Financial Results: Procter & Gamble Health
NATCO Pharma Limited Q3FY23 Earnings
A pharmaceutical firm with a strong focus on research and development, NATCO Pharma Ltd creates, produces, and markets sophisticated pharmaceuticals for specialised
Pfizer Limited Q3FY23 Earnings Story
Pfizer Ltd is primarily involved in marketing, exporting, manufacturing, and trading of pharmaceutical products. It produces goods through its in-house facility and
Panacea Biotec Q3FY23; 26% Fall in Revenue
Panacea Biotec Limited’s revenue in Q3FY23 fell 26% to ₹ 11,520 lakhs. Consolidated Profit After Tax came at ₹ 1,937 lakhs in
Lupin Ltd (LUPIN) Q3 FY23 Earnings Concall Transcript
Lupin Ltd (NSE:LUPIN) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Vinita Gupta -- Chief Executive Officer Ramesh Swaminathan -- Executive Director, Global Chief
Lupin Limited Q3FY23; 47% Growth in Profits
Lupin Limited’s revenue in Q3FY23 rose 13% to ₹ 1,97,66,301 lakhs. Consolidated Profit After Tax came at ₹ 8,34,871 lakhs in Q3FY23